Stock ROVI LABORATORIOS FARMACEUTICOS ROVI, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

News Laboratorios Farmaceuticos Rovi, S.A.

Equities

ROVI

ES0157261019

Market Closed - BME
Other stock markets
 11:35:23 2024-05-28 am EDT 		5-day change 1st Jan Change
88.5 EUR -1.01% Intraday chart for Laboratorios Farmaceuticos Rovi, S.A. +0.34% +47.01%
May. 08 Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 02 Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Laboratorios Farmaceuticos Rovi S A : First three months 2024 results press release
PU
Laboratorios Farmaceuticos Rovi S A : ROVI announces agreement to manufacture pre-filled syringes
PU
Spain's Rovi Obtains US FDA Approval for Marketing Risvan as Schizophrenia Treatment
MT
Rovi, Partners to Form Entity for Advanced Therapies R&D
MT
Laboratorios Farmaceuticos Rovi S A : ROVI, Insud Pharma and Innvierte (CDTI) create a company for the research and development of advanced therapies
PU
Rovi explores sale of unit that makes drugs for third parties
RE
Rovi Responds to Press Speculation Regarding Contract Development Business Deal
MT
Transcript : Laboratorios Farmaceuticos Rovi, S.A., 2023 Earnings Call, Feb 27, 2024
The Ibex-35 opts for caution as corporate results continue to trickle in.
RE
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
US FDA finds control lapses at Moderna manufacturing plant
RE
Italy, Spain stocks hit peaks after over 20% rally in 2023
RE
Laboratorios Farmaceuticos Rovi S A : First nine months 2023 results press release
PU
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Laboratorios Farmaceuticos Rovi S A : ROVI informs on the evaluation process to obtain marketing authorisation for Risvan®
PU
Transcript : Laboratorios Farmaceuticos Rovi, S.A., H1 2023 Earnings Call, Jul 26, 2023
Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Tranche Update on Laboratorios Farmaceuticos Rovi, S.A.'s Equity Buyback Plan announced on November 3, 2021.
CI
Laboratorios Farmaceuticos Rovi S A : First half 2023 results press release
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ROVI Stock
  4. News Laboratorios Farmaceuticos Rovi, S.A.